HRP20150442T1 - Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti - Google Patents
Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti Download PDFInfo
- Publication number
- HRP20150442T1 HRP20150442T1 HRP20150442TT HRP20150442T HRP20150442T1 HR P20150442 T1 HRP20150442 T1 HR P20150442T1 HR P20150442T T HRP20150442T T HR P20150442TT HR P20150442 T HRP20150442 T HR P20150442T HR P20150442 T1 HRP20150442 T1 HR P20150442T1
- Authority
- HR
- Croatia
- Prior art keywords
- piperazin
- methyl
- benzamide
- sulfonyl
- chloro
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- -1 3-nitrophenyl Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- GPPPXKNVTFBSTL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 GPPPXKNVTFBSTL-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000006491 bone marrow cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000005443 oral cavity cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000002471 spleen cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FJZOQMFIORMRLP-UHFFFAOYSA-N 2-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)S(=O)(=O)C=2C=CC=CC=2)=C1 FJZOQMFIORMRLP-UHFFFAOYSA-N 0.000 claims 1
- IWWJPGBIUYUWNK-UHFFFAOYSA-N 2-(benzylamino)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)NCC=2C=CC=CC=2)=C1 IWWJPGBIUYUWNK-UHFFFAOYSA-N 0.000 claims 1
- HXRVIEGQHHOCPR-UHFFFAOYSA-N 2-benzyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)CC=2C=CC=CC=2)=C1 HXRVIEGQHHOCPR-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- BNVIHDHSEOBSNQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-isoquinolin-5-ylsulfonylbenzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=CC=3)C(C(=O)NS(=O)(=O)C=3C4=CC=NC=C4C=CC=3)=CC=2)=C1C1=CC=C(Cl)C=C1 BNVIHDHSEOBSNQ-UHFFFAOYSA-N 0.000 claims 1
- GDQMKMHGQSDLMZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-naphthalen-2-ylsulfonylbenzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=CC=3)C(C(=O)NS(=O)(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=C(Cl)C=C1 GDQMKMHGQSDLMZ-UHFFFAOYSA-N 0.000 claims 1
- FNICTEPHDSTAQD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-chlorophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(Cl)=C1 FNICTEPHDSTAQD-UHFFFAOYSA-N 0.000 claims 1
- SIJDUBGMHLDPBT-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-cyanophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(C#N)=C1 SIJDUBGMHLDPBT-UHFFFAOYSA-N 0.000 claims 1
- VPXJBJXSVQXVCJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC(F)=C1 VPXJBJXSVQXVCJ-UHFFFAOYSA-N 0.000 claims 1
- CNZAMKRFZAFZPG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 CNZAMKRFZAFZPG-UHFFFAOYSA-N 0.000 claims 1
- DRLIZTXBELGBKR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-methoxy-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound COC1=CC(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 DRLIZTXBELGBKR-UHFFFAOYSA-N 0.000 claims 1
- SRGBCJUILFABMC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(2-chloropyridin-3-yl)sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C(=NC=CC=2)Cl)CC1 SRGBCJUILFABMC-UHFFFAOYSA-N 0.000 claims 1
- JRZLWSQYQUWPCR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(2-oxochromen-6-yl)sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3C=CC(=O)OC3=CC=2)CC1 JRZLWSQYQUWPCR-UHFFFAOYSA-N 0.000 claims 1
- HCTAJBQMMLMSJI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonyl-2-phenoxybenzamide Chemical compound FC1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 HCTAJBQMMLMSJI-UHFFFAOYSA-N 0.000 claims 1
- SUIJTQPTRDUPEB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-fluorophenyl)sulfonylbenzamide Chemical compound FC1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=C1 SUIJTQPTRDUPEB-UHFFFAOYSA-N 0.000 claims 1
- FISAKEDWNVTBGH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 FISAKEDWNVTBGH-UHFFFAOYSA-N 0.000 claims 1
- KBVMHTSIMLRIFA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenylmethoxybenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OCC=2C=CC=CC=2)=C1 KBVMHTSIMLRIFA-UHFFFAOYSA-N 0.000 claims 1
- KOJIENBSLDFNMM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonyl-2-phenylsulfanylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)SC=2C=CC=CC=2)=C1 KOJIENBSLDFNMM-UHFFFAOYSA-N 0.000 claims 1
- CQEPWMHPRDDCIE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=C1 CQEPWMHPRDDCIE-UHFFFAOYSA-N 0.000 claims 1
- BXEISNUVXAJJAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-fluorophenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 BXEISNUVXAJJAI-UHFFFAOYSA-N 0.000 claims 1
- OWKDGYAQXUCVCU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-fluorophenyl)sulfonylbenzamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 OWKDGYAQXUCVCU-UHFFFAOYSA-N 0.000 claims 1
- VKQPRWICDULKPK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-hydroxyphenyl)sulfonylbenzamide Chemical compound C1=CC(O)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 VKQPRWICDULKPK-UHFFFAOYSA-N 0.000 claims 1
- MCSIRHQHADGDEE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-nitrophenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 MCSIRHQHADGDEE-UHFFFAOYSA-N 0.000 claims 1
- MGTVGTCWJPGPAY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-nitrophenyl)sulfonylbenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 MGTVGTCWJPGPAY-UHFFFAOYSA-N 0.000 claims 1
- CKFOSMPIIUFZEI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[(3-oxo-4h-1,4-benzoxazin-6-yl)sulfonyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3NC(=O)COC3=CC=2)CC1 CKFOSMPIIUFZEI-UHFFFAOYSA-N 0.000 claims 1
- XHQMEZQMJATMTR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)sulfonyl]benzamide Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 XHQMEZQMJATMTR-UHFFFAOYSA-N 0.000 claims 1
- ITJFDFILFDAJGH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[5-[ethyl-(2,2,2-trifluoroacetyl)amino]naphthalen-1-yl]sulfonylbenzamide Chemical compound C1=CC=C2C(N(C(=O)C(F)(F)F)CC)=CC=CC2=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 ITJFDFILFDAJGH-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- DCKVKZZRSYAHLG-UHFFFAOYSA-N n-(3-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(Br)C=CC=2)CC1 DCKVKZZRSYAHLG-UHFFFAOYSA-N 0.000 claims 1
- QMHHGDNHDXXPHX-UHFFFAOYSA-N n-(4-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(CCCC1)=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC(Br)=CC=2)CC1 QMHHGDNHDXXPHX-UHFFFAOYSA-N 0.000 claims 1
- MYKWZSCCXSEBGS-UHFFFAOYSA-N n-(4-bromophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC(Br)=CC=2)CC1 MYKWZSCCXSEBGS-UHFFFAOYSA-N 0.000 claims 1
- XPOXAYYAILGHKP-UHFFFAOYSA-N n-(4-chloro-3-nitrophenyl)sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-phenoxybenzamide Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=C1 XPOXAYYAILGHKP-UHFFFAOYSA-N 0.000 claims 1
- UILCCKJHTVYDMB-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[(4-phenylphenyl)methyl]-3-propan-2-ylpiperazin-1-yl]benzamide Chemical compound CC(C)C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC=CC=2)CCN1CC(C=C1)=CC=C1C1=CC=CC=C1 UILCCKJHTVYDMB-UHFFFAOYSA-N 0.000 claims 1
- MOAGJICESAJPLQ-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 MOAGJICESAJPLQ-UHFFFAOYSA-N 0.000 claims 1
- UWDCQUANIFFSJC-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)benzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=CC=C1 UWDCQUANIFFSJC-UHFFFAOYSA-N 0.000 claims 1
- UXWMBCNLSPHYRM-UHFFFAOYSA-N n-(benzenesulfonyl)-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=CC=CC=2)CC1 UXWMBCNLSPHYRM-UHFFFAOYSA-N 0.000 claims 1
- ZTPGNUQTWVCEHN-UHFFFAOYSA-N n-[(6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-7-yl)sulfonyl]-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C(=CC3=C(S(NC=N3)(=O)=O)C=2)Cl)CC1 ZTPGNUQTWVCEHN-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14562709P | 2009-01-19 | 2009-01-19 | |
EP12163746.6A EP2511264B1 (fr) | 2009-01-19 | 2010-01-15 | Agents induisant l'apoptose pour le traitement du cancer et de maladies immunes et auto-immunes |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150442T1 true HRP20150442T1 (hr) | 2015-05-22 |
Family
ID=42026765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150442TT HRP20150442T1 (hr) | 2009-01-19 | 2015-04-23 | Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti |
Country Status (24)
Country | Link |
---|---|
US (1) | US8426422B2 (fr) |
EP (2) | EP2387560A2 (fr) |
JP (1) | JP5613176B2 (fr) |
KR (2) | KR101661126B1 (fr) |
CN (2) | CN106045893A (fr) |
AU (1) | AU2010204554B2 (fr) |
BR (1) | BRPI1006116A2 (fr) |
CA (2) | CA2936120A1 (fr) |
DK (1) | DK2511264T3 (fr) |
ES (1) | ES2536090T3 (fr) |
HK (1) | HK1177206A1 (fr) |
HR (1) | HRP20150442T1 (fr) |
HU (1) | HUE025527T2 (fr) |
IL (2) | IL213623A (fr) |
MX (1) | MX2011007681A (fr) |
NZ (3) | NZ593593A (fr) |
PL (1) | PL2511264T3 (fr) |
PT (1) | PT2511264E (fr) |
RU (1) | RU2539587C2 (fr) |
SG (2) | SG193849A1 (fr) |
SI (1) | SI2511264T1 (fr) |
TW (2) | TWI494303B (fr) |
WO (1) | WO2010083441A2 (fr) |
ZA (1) | ZA201104672B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
HUE028175T2 (en) * | 2008-11-07 | 2016-12-28 | Amgen Res (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
HUE025452T2 (en) * | 2008-11-07 | 2016-05-30 | Amgen Res (Munich) Gmbh | A new procedure for the treatment of acute lymphoid leukemia in childhood |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
PL2511264T3 (pl) | 2009-01-19 | 2015-08-31 | Abbvie Inc | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
ME02205B (me) * | 2009-05-26 | 2016-02-20 | Abbvie Bahamas Ltd | INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN105218483A (zh) | 2010-03-25 | 2016-01-06 | Abbvie公司 | 用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂 |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
KR20180059560A (ko) * | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
AU2011332043C1 (en) * | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
UY33746A (es) | 2010-11-23 | 2012-06-29 | Abbott Lab | Método de tratamiento que usa inhibidores selectivos de bcl-2 |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
MX2014007093A (es) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Metodos para mejorar terapias medicas. |
WO2013158664A2 (fr) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Utilisation de virus modifiés pour tuer spécifiquement les cellules sénescentes |
KR101229430B1 (ko) * | 2012-07-02 | 2013-02-05 | 대한민국 | 〔e〕n〔5〔2〔2〔2,4다이히드록시벤질리덴〕히드라지닐〕2옥소에틸〕1,3,4티아디아졸2일〕4메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환의 예방 및 치료용 약학적 조성물 |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
RS57569B1 (sr) * | 2013-03-13 | 2018-10-31 | Abbvie Inc | Postupci za pripremanje agensa koji uzrokuje apoptozu |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
WO2015116735A1 (fr) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Procédés et combinaisons pour tuer des cellules sénescentes et traiter des maladies et troubles associés à une sénescence |
CA3100140C (fr) | 2014-01-28 | 2023-10-24 | Buck Institute For Research On Aging | Procedes et compositions permettant de detruire les cellules senescenteset de traiter les maladies et les troubles associes a la senescence |
CA2938571C (fr) | 2014-02-03 | 2020-12-22 | Quadriga Biosciences, Inc. | Acides beta-amines substitues en beta et analogues en tant qu'agents de chimiotherapie |
EP3169326B1 (fr) * | 2014-07-15 | 2021-03-31 | The Johns Hopkins University | Suppression de cellules suppressives d'origine myéloïde et blocage de point de contrôle immunitaire |
NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2016085391A1 (fr) * | 2014-11-27 | 2016-06-02 | Acturum Life Science AB | Dérivés de bis (sulfonamide) etleur utilisation comme inhibiteurs de mpges |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
TWI665178B (zh) | 2015-08-03 | 2019-07-11 | 夸德里加生物科學公司 | 作為化療劑的β-取代的β-氨基酸和類似物及其應用 |
CN107033043B (zh) * | 2016-02-04 | 2019-04-30 | 中国人民解放军第二军医大学 | N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途 |
WO2017173274A1 (fr) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN106565706B (zh) * | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
AU2017371200B2 (en) | 2016-12-09 | 2021-05-06 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
TWI651087B (zh) * | 2017-04-21 | 2019-02-21 | 長庚大學 | 類泛素化抑制劑於預防或治療骨質疏鬆症的用途 |
AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
KR20200097293A (ko) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
EP3774825A1 (fr) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
CN117430601A (zh) | 2018-04-29 | 2024-01-23 | 百济神州有限公司 | Bcl-2抑制剂 |
CN109776414B (zh) * | 2019-01-02 | 2022-04-22 | 山东大学 | 一种Bcl-2蛋白抑制剂及其制备方法和应用 |
WO2021180040A1 (fr) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | Composé cyclique à cinq chaînons benzo |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
AU6964096A (en) | 1995-09-15 | 1997-04-01 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
DE60129741T2 (de) * | 2000-06-20 | 2008-04-30 | Immunomedics, Inc. | Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
JP4167173B2 (ja) * | 2001-06-06 | 2008-10-15 | イーライ リリー アンド カンパニー | 抗腫瘍剤としての使用のためのベンゾイルスルホンアミドおよびスルホンベンズアミジン |
US20030059489A1 (en) | 2001-09-24 | 2003-03-27 | Canolio Inc. | Genital lubricating compositions and uses thereof |
US7332486B2 (en) | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US6995787B2 (en) | 2002-08-21 | 2006-02-07 | Adams Steven L | Sports projectile and camera apparatus |
JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
AU2004278030C1 (en) | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (fr) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
NZ561609A (en) * | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
MX2007014783A (es) * | 2005-05-24 | 2008-02-19 | Abbott Lab | Activadores de apoptosis. |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するbclインヒビター |
US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
WO2008098857A1 (fr) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines comme ligands de taar1 |
EP2148867B1 (fr) | 2007-04-19 | 2014-09-10 | Concert Pharmaceuticals Inc. | Composés substitués de morpholinyle |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
WO2009036035A1 (fr) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Inhibiteurs de bcl-2 |
WO2009036051A1 (fr) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Inhibiteurs de la bcl-2 contenant une fraction de liaison au zinc |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
WO2009051782A1 (fr) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Étravirine deutérée |
CA2703591C (fr) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Darunavir deutere |
CN101220008B (zh) * | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA2744711C (fr) * | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Agents induisant l'apoptose selectifs pour bcl-2 pour le traitement du cancer et des maladies immunes |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
PL2511264T3 (pl) | 2009-01-19 | 2015-08-31 | Abbvie Inc | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
ME02205B (me) | 2009-05-26 | 2016-02-20 | Abbvie Bahamas Ltd | INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN105218483A (zh) | 2010-03-25 | 2016-01-06 | Abbvie公司 | 用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂 |
-
2010
- 2010-01-15 PL PL12163746T patent/PL2511264T3/pl unknown
- 2010-01-15 NZ NZ593593A patent/NZ593593A/xx not_active IP Right Cessation
- 2010-01-15 CN CN201610390761.1A patent/CN106045893A/zh active Pending
- 2010-01-15 SI SI201030944T patent/SI2511264T1/sl unknown
- 2010-01-15 EP EP10701083A patent/EP2387560A2/fr not_active Withdrawn
- 2010-01-15 ES ES12163746.6T patent/ES2536090T3/es active Active
- 2010-01-15 CA CA2936120A patent/CA2936120A1/fr not_active Abandoned
- 2010-01-15 SG SG2013066071A patent/SG193849A1/en unknown
- 2010-01-15 HU HUE12163746A patent/HUE025527T2/en unknown
- 2010-01-15 EP EP12163746.6A patent/EP2511264B1/fr active Active
- 2010-01-15 KR KR1020117018581A patent/KR101661126B1/ko active IP Right Grant
- 2010-01-15 SG SG2011046836A patent/SG172391A1/en unknown
- 2010-01-15 WO PCT/US2010/021243 patent/WO2010083441A2/fr active Application Filing
- 2010-01-15 BR BRPI1006116A patent/BRPI1006116A2/pt not_active IP Right Cessation
- 2010-01-15 MX MX2011007681A patent/MX2011007681A/es active IP Right Grant
- 2010-01-15 NZ NZ703941A patent/NZ703941A/en not_active IP Right Cessation
- 2010-01-15 JP JP2011546401A patent/JP5613176B2/ja not_active Expired - Fee Related
- 2010-01-15 RU RU2011134634/04A patent/RU2539587C2/ru not_active IP Right Cessation
- 2010-01-15 NZ NZ61682810A patent/NZ616828A/en not_active IP Right Cessation
- 2010-01-15 PT PT121637466T patent/PT2511264E/pt unknown
- 2010-01-15 CA CA2747835A patent/CA2747835A1/fr not_active Abandoned
- 2010-01-15 KR KR1020167014664A patent/KR20160066014A/ko active IP Right Grant
- 2010-01-15 AU AU2010204554A patent/AU2010204554B2/en not_active Ceased
- 2010-01-15 CN CN2010800047718A patent/CN102282129A/zh active Pending
- 2010-01-15 DK DK12163746.6T patent/DK2511264T3/da active
- 2010-01-18 US US12/689,106 patent/US8426422B2/en not_active Expired - Fee Related
- 2010-01-18 TW TW104101224A patent/TWI494303B/zh not_active IP Right Cessation
- 2010-01-18 TW TW99101256A patent/TWI472527B/zh not_active IP Right Cessation
-
2011
- 2011-06-16 IL IL213623A patent/IL213623A/en not_active IP Right Cessation
- 2011-06-23 ZA ZA2011/04672A patent/ZA201104672B/en unknown
-
2013
- 2013-04-11 HK HK13104411.8A patent/HK1177206A1/xx not_active IP Right Cessation
-
2015
- 2015-04-23 HR HRP20150442TT patent/HRP20150442T1/hr unknown
- 2015-05-04 IL IL238607A patent/IL238607A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150442T1 (hr) | Sredstva za izazivanje apoptoze za lijeäśenje raka i imunih i autoimunih bolesti | |
RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
NZ724602A (en) | Ror-gamma modulators and uses thereof | |
CA2606783C (fr) | Modulateurs de l'indolamine 2,3-dioxygenase et leurs procedes d'utilisation | |
JP2007519754A5 (fr) | ||
RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
JP2008545686A5 (fr) | ||
RU2020108515A (ru) | Соединения и способы целевого расщепления андрогенного рецептора | |
JP2017527578A5 (fr) | ||
IL295487A (en) | gcn2 modulator compounds | |
JP2015517981A5 (fr) | ||
RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
JP2016503786A5 (fr) | ||
JP2008524244A5 (fr) | ||
RU2015141713A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
RU2007107189A (ru) | Производные арилпиридина | |
CA2582029A1 (fr) | Composes bicycliques contenant un arylazide et methodes d'utilisation deceux-ci | |
JP2011529037A5 (fr) | ||
JP2013516395A5 (fr) | ||
EA016687B8 (ru) | Производные циклопропиламида | |
DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 |